Adamis Pharma Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Adamis Pharma prevailing Real Value cannot be determined due to lack of data. The current price of Adamis Pharma is $0.0. Our model approximates the value of Adamis Pharma from analyzing the firm fundamentals such as operating margin of (3.74) %, and Return On Equity of -7.85 as well as examining its technical indicators and probability of bankruptcy.
Adamis Pharma Total Value Analysis
Adamis Pharma is presently expected to have valuation of 7.28 M with market capitalization of 7.25 M, debt of 342.56 K, and cash on hands of 8.88 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Adamis Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.28 M | 7.25 M | 342.56 K | 8.88 M |
Adamis Pharma Investor Information
About 17.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 10.14. Adamis Pharma had not issued any dividends in recent years. The entity had 1:70 split on the 22nd of May 2023. Based on the key measurements obtained from Adamis Pharma's financial statements, Adamis Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Adamis Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adamis Pharma has an asset utilization ratio of 43.51 percent. This connotes that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Adamis Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Adamis Pharma Ownership Allocation
Adamis Pharma shows 7.81 percent of its outstanding shares held by insiders and 16.59 percent owned by other corporate entities.Adamis Pharma Profitability Analysis
The company reported the previous year's revenue of 4.76 M. Net Loss for the year was (26.48 M) with loss before overhead, payroll, taxes, and interest of (1.43 M).Adamis Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Adamis Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 149.9 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Adamis Stock
If you are still planning to invest in Adamis Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adamis Pharma's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |